Lunning and Maddocks Talk Through Frontline MCL Management

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sat down with Kami J. Maddocks, MD, to discuss the management of mantle cell lymphoma (MCL) in the up-front setting. Dr Maddocks is a professor in the Division of Hematology at The Ohio State University, as well as medical director of Infusion Services at The Ohio State University Comprehensive Cancer Center––James in Columbus.

Drs Lunning and Maddocks highlighted practice-changing findings from the phase 3 SHINE (NCT01776840) and TRIANGLE (NCT02858258) trials; detailed how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for patients with MCL; explained how patient characteristics, such as age and TP53 mutation status affect up-front treatment feasibility, and more.